Paul Andrew Hamblin

This inventor holds 13 USPTO granted patents and 27 published patent applications, plus 4 CIPO patents and 6 EPO patents. Top assignees: Glaxo Group Limited, Glaxosmithkline Intellectual Property Development Limited. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul Andrew Hamblin. Retrieved from https://idiyas.com/inventor/paul-andrew-hamblin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 27)

% Patents Active = 76.9

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 22)

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 29(Granted Patents)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

patents

Years Active: 2010-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12466893 - ANTIGEN BINDING PROTEINS (2025-11-11),

2. 11419945 - Antigen binding proteins (2022-08-23),

3. 10703814 - Method of treatment with humanized anti-IL-18 antibodies (2020-07-07),

4. 10344088 - Antigen binding proteins (2019-07-09),

5. 10280221 - Anti-LAG-3 binding proteins (2019-05-07),

6. 9499617 - Humanized anti-IL-18 antibodies (2016-11-22),

7. 9394374 - Antigen-binding proteins (2016-07-19),

8. 9273141 - B cell maturation antigen (BCMA) binding proteins (2016-03-01),

9. 8680245 - IL-13 binding protein (2014-03-25),

10. 8637018 - Humanized anti-IL-18 antibodies (2014-01-28),

11. 8362208 - Immunoglobulins (2013-01-29),

12. 8133978 - Humanised anti-interleukin-18 antibody (2012-03-13),

13. 7780964 - Immunoglobulins which bind NOGO (2010-08-24),

Title: Paul Andrew Hamblin: Innovator in Antigen Binding Proteins and Antibodies

Introduction

Paul Andrew Hamblin is a notable inventor based in Stevenage, GB, with a remarkable portfolio of 12 patents. His work primarily focuses on advancements in the field of biotechnology, particularly in the development of antigen binding proteins and therapeutic antibodies.

Latest Patents

Among his latest patents, Hamblin has developed antigen binding proteins that specifically target B Cell Maturation Antigen (BCMA). These proteins inhibit the binding of BAFF and APRIL to the BCMA receptor, offering potential therapeutic applications. Additionally, he has disclosed methods of treatment using humanized anti-IL-18 antibodies, which include manufacturing processes and screening methods to identify antibodies with therapeutic potential.

Career Highlights

Throughout his career, Hamblin has contributed significantly to the pharmaceutical industry. He has worked with prominent companies such as Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited, where he has played a crucial role in advancing medical research and innovation.

Collaborations

Some of his notable coworkers include Alan Peter Lewis and Jonathan Henry Ellis, who have collaborated with him on various projects, enhancing the scope and impact of their research.

Conclusion

Paul Andrew Hamblin's contributions to the field of biotechnology through his patents and collaborations highlight his innovative spirit and dedication to advancing medical science. His work continues to pave the way for new therapeutic solutions.

Profile summary based on public USPTO records.